Autorentext
Alberto Espay is Professor of Neurology and Endowed Chair of the University of Cincinnati James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders. He has published extensively on Parkinson's disease and leads the first phenotype-agnostic biomarker development program for patients with neurodegenerative diseases (CCBP) designed to deploy bioassays aiming at matching available therapies with those most likely to benefit, regardless of their clinical diagnosis. Benjamin Stecher was diagnosed with Parkinson's Disease aged 29 and has since become actively involved in Parkinson's Disease research and advocacy. He is the founder of Tomorrow Edition, where he has interviewed close to 80 experts in Parkinson's disease. He sits on several patient advisory boards and speaks and consults regularly at academic labs, as well as biotech and pharmaceutical companies, working to bring better therapies for people diagnosed with Parkinson's disease.

Klappentext
With no biological boundaries between neurodegenerative diseases as defined today, Brain Fables offers a blueprint for precision medicine.

Inhalt

Preface; Acknowledgements; 1. The shaky six and the 'second reality'; 2. Pieces of a puzzle?; 3. Disease 'redefinition': a tough pill to swallow; 4. Disease subtypes: the promise and the fallacy; 5. Protein paradox; 6. The fault in our models; 7. Biomarkers: the promise and the fallacy; 8. Lessons from oncology; 9. Symptomatic vs. disease-modifying therapies; 10. The hypothesis that refuses to die; 11. Our living dissonance; 12. The scientific and lay narratives; 13. Challenges viewed from afar; 14. The moonshot: population-based studies of aging; 15. Predictions for the 2020s and beyond; Epilogue. 'When will we have a cure for Parkinson's disease?"; Note added at press time; References; Index.